Because these inhibitors yield encouraging clinical results in other cancers, our findings indicate a rational therapeutic strategy for treating a subset of pediatric astrocytomas with BRAFV600E mutation and CDKN2A deficiency. The gene discussed is CDKN2A; the disease is astrocytoma (excluding glioblastoma).